IRCT20200105046010N75RecruitingUnknown
Bioequivalence study of Sunitinib 50 mg capsule manufactured by Zistdaru Danesh (Sunixha) versus Sutent 50 mg in healthy volunteers in the fasted condition
Trial Snapshot
- Phase
- Unknown
- Status
- Recruiting
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 55 years (—)
- Sex
- All
Inclusion Criteria
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
Exclusion Criteria
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to Sunitinib
Investigators
Similar Trials
Completed
Not Applicable
A bioequivalence study of Sunitinib 50 mg capsules of Sobhanoncology compared to Sutent 50 mg Capsule manufactured by Pfizer in 24 healthy volunteers under fasting conditioBioequivalence study.IRCT20220209053979N3Sobhan Oncology24
Recruiting
Not Applicable
Bioequivalence study of Nilotinib 200mg capsuleThis study is performed on healthy volunteers..IRCT20200623047902N21Zistdaru danesh Co.24
Not yet recruiting
Not Applicable
Bioequivalence study of Nilotinib 200mg capsuleThis study is performed on healthy volunteers..IRCT20200623047902N17Rooyan darou company24
Completed
Phase 1
A Bioequivalence Study of Sunitinib Malate Capsules.Gastrointestinal Stromal TumorsRenal Cell CarcinomaPancreatic Neuroendocrine TumorNCT05800106Chia Tai Tianqing Pharmaceutical Group Co., Ltd.24
Recruiting
Not Applicable
Bioequivalence study of Dasatinib 50 mg tabletIRCT20200623047902N22Zistdaru danesh Co.48